Fabhalta lowered likelihood of progression to kidney failure by 43% in APPLAUSE-IgAN study140.7% of patients on Fabhalta demonstrated sustained reduction...
As interest in the gelatin trick surges in 2026, consumers across social platforms and search engines are asking whether the...
A 2026 report outlining Steel Power ingredient research, male enhancement supplement positioning, performance claim context, pricing structure, and what the...
In the Phase 2 part of the AMETHYST study, litifilimab met the primary endpoint of reduction of disease activity in...
The results of the Phase 3 VALOR trial were published in the New England Journal of Medicine, underscoring the practice-changing...
Results from the Phase 3 VELA clinical trials in adults with moderate-to-severe hidradenitis suppurativa (HS) show that clinical responses continue...
A 2026 informational consumer evaluation of Gelatide marketing claims, ingredient research context, Akkermansia muciniphila and proprietary blend dosage transparency, the...
Envudeucitinib achieved robust PASI responses by Week 16, with significant continued improvements by Week 24 in PASI 90 (68.0%, 62.1%) and PASI...
A 2026 informational overview of the SonusZen hearing support formulation, Sonus Zen ingredient transparency and B vitamin research context, tinnitus...
Investigational ZORYVE® (roflumilast) cream 0.05% was well tolerated with safety findings consistent with prior pediatric experience in the INTEGUMENT programZORYVE...
Featured presentation highlights positive BroADen Phase 1b atopic dermatitis trial results supporting KT-621’s compelling oral profile Parallel Phase 2b trials,...
AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session Across the COAST...